Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography
Status:
Unknown status
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This is a PI-initiated study taking place only at UCLA, sponsored by Sunovion. The
investigators plan to enroll about 20 subjects who are at least 40 years old and have Chronic
Obstructive Pulmonary Disease (COPD). The purpose of this study is to compare the
effectiveness of Brovana and Serevent in helping relieve COPD symptoms. Specifically, the
investigators are looking at how much and for how long the two drugs can open up the small
airways in the lungs. This will be done with breathing tests on all subjects, and with high
resolution CT scans on subjects who agree to this optional part of the study. Half of
subjects will take Brovana (arformoterol tartrate inhalation solution) for 2 weeks and then
Serevent (salmeterol xinafoate inhalation powder) for 2 weeks; the other half will take
Serevent the first two weeks and Brovana the second two weeks. All subjects will also take
Spiriva (tiotropium) and will be provided with albuterol for immediate relief of symptoms.
After a Screening Visit to determine eligibility, subjects will be randomly assigned to
receive Brovana or Serevent for the first 2 weeks, complete Test Visit 1, then receive the
other study drug for 2 weeks, and finally complete Test Visit 2. Visits will include
questionnaires, review of health and medications, and breathing tests before and after taking
the study drug. Subjects who agree to be in the sub-study will also undergo CT scans before
and after taking the study drug at both test visits.